Aprocitentan - Idorsia Pharmaceuticals

Drug Profile

Aprocitentan - Idorsia Pharmaceuticals

Alternative Names: AC 080; ACT-132577

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals; Janssen Biotech
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase I Cardiovascular disorders

Most Recent Events

  • 20 Jun 2018 Phase-III clinical trials in Hypertension (Treatment-experienced) in Switzerland (PO) (NCT03541174)
  • 06 Feb 2018 Idorsia Pharmaceuticals plans the phase III PRECISION registrational trial for Hypertension (Treatment experienced) in the first half of 2018 (PO, Tablet) (NCT03541174)
  • 29 Jan 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top